Faropenem medoxomil

Class: Beta-lactam

Spectrum of activity:	Gram-negative
Details of activity:	Being developed for the treatment of community acquired pneumonia
Institute where first reported:	Asubio Pharma
Year first mentioned:	1995
Highest developmental phase:	Phase 3 (suspended)
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C[C@H]([C@H]1C(=O)N2C(=C([C@H]3CCCO3)S[C@H]12)C(=O)OCC4=C(C)OC(=O)O4)O
Isomeric SMILES:	CC1=C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4
InChI:	InChI=1S/C17H19NO8S/c1-7(19)11-14(20)18-12(13(27-15(11)18)9-4-3-5-23-9)16(21)24-6-10-8(2)25-17(22)26-10/h7,9,11,15,19H,3-6H2,1-2H3/t7-,9-,11+,15-/m1/s1
InChI Key:	JQBKWZPHJOEQAO-DVPVEWDBSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/6918218

External links:
Guide to Pharmacology:	faropenem
Main Source:	https://journals.asm.org/doi/10.1128/aac.01566-08